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AbstrAct
Bone histomorphometry is defined as a quantitative
evaluation of bone micro architecture, remodelling and
metabolism. Bone metabolic assessment is based on a
dynamic process, which provides data on bone matrix
formation rate by incorporating a tetracycline com-
pound. In the static evaluation, samples are stained and
a semi-automatic technique is applied in order to ob-
tain bone microarchitectural parameters such as tra-
becular area, perimeter and width. These parameters
are in 2D, but they can be extrapolated into 3D, 
applying a stereological formula. 
Histomorphometry can be applied to different 
areas; however, in recent decades it has been a relevant
tool in monitoring the effect of drug administration in
bone. 
The main challenge for the future will be the de -
velop ment of noninvasive methods that can give simi-
lar information.
In the herein review paper we will discuss the gene -
ral principles and main applications of bone histomor-
phometry.
Keywords: Histomorphometry; Bone; Bone biopsy;
Bone metabolic diseases.
IntroductIon
Bone histomorphometry allows the quantitative study
of bone microscopic organization and structure. 
In 1960, Harold Frost1, an American orthopaedic sur-
geon, pioneered the study of metabolism, mass and
structure of bone, boosting histomorphometry as a
technique.
Parfitt in 19802, 3 stressed the importance of the study of
bone microarchitecture and proposed a set of stereo-
logical techniques for its measurement. These tech-
niques would later be used worldwide giving rise to sys-
tems of classification, rules and standardization of mea-
surement units. Five years later, the Committee of 
the American Society of Bone and Mineral Research 
(ASBMR) decided to put together worldwide researchers
to establish common terminology fostering the scientif-
ic evolution of the technique. Bone biopsy evaluation 
is performed in un-decalcified (mineralized) bone sam-
ples in order to obtain qualitative and quantitative data
about the microarchitecture and metabolism of bone4.
Bone, as all connective tissues, is composed of cells
and an extracellular matrix mainly comprised of a col-
lagen type I network impregnated with hydroxyapatite
mineral crystals. The cortical bone is compact, ener-
vated and vascularized. Cortical bone is present in the
epiphyses of long bones and coats the bones of the
body, giving rigidity and strength. The trabecular part
of bone is formed by a network of trabeculae, which
confers resistance to compression. 
Bone is constantly remodelled by the dual action 
of two cell types, osteoclasts and osteoblasts. Osteo-
clasts resorb bone whereas osteoblasts form new bone
in a process known as remodelling. This process is re-
quired for the development and maintenance of the
bone tissue and its imbalance leads to bone diseases
such as osteoporosis. Remodelling occurs at bone sur-
face and its rate is higher in trabecular in comparison
to cortical bone5. The analysis of bone microarchitec-
ture is crucial for the detection of metabolic bone di -
seases, therefore histomorphometry can be used in se -
veral areas as a crucial tool in monitoring bone pro-
cesses and the effect of drugs6-10. In this paper, the 
authors describe practical aspects of the histomor-
phometry technique, which may be useful as a guide for
researchers who would like to take advantage of its pos-
sibilities.
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sAmplE prEpArAtIon
bonE bIopsy
The standard procedure involves the extration of the
bone sample from the iliac crest following a systema -
tized technique1. A small incision (two centimetres be-
low and behind the anterior superior iliac spine) is
made through the skin to achieve access to the exter-
nal wall of the iliac crest by using a 5 to 8mm
trephine,11-13 which allows the removal of a cylindrical
sample of bone (Figure 1). The sample is composed of
an internal and external layers of cortical bone sepa-
rated by an intermediate region of trabecular bone1,14,15.
After the biopsy, the bone sample is processed in order
to maintain its stiffness while it is being cut.
sAmplE procEssInG
Once the bone sample is collected, it is crucial to car-
ry out the processing steps in order to prevent the de-
terioration of the tissue triggered by proteolytic en-
zymes and, at a later stage, to preserve its microarchi-
tecture. 
The different stages of processing have critical
points concerning the preservation of microarchitec-
ture. Thus, it is essential to optimize the contact time
and temperature between the chemicals and the sam-
ple as insufficient fixation causes sample shrinkage,
which subsequently leads structural distortions that
can abolish histological evaluations.
Sample processing includes five steps: fixation, de-
hydration, clearing, impregnation and embedding13.
Fixation is used to control the proteolytic processes
and bacteria proliferation. This stage takes place in al-
cohol 70% for a minimum of 72 hours at 5ºC. 
After fixation, the water in the tissue must be re-
moved so that the sample can be placed in an impreg-
nation solution, which is immiscible with water. This
process is called dehydration and is achieved by in-
creasing ethanol saturation from 96% to 100% over a
period of 24 hours at 5ºC. 
The next step is clearing in which the alcohol pre-
sent in the bone tissue from the last step (dehydration)
is replaced by an intermediate solution, Xylene for 24
hours at 5ºC, after which the sample becomes clear
and transparent. 
In the impregnation step the sample is embedded in
methyl methacrylate for a minimum of 72 hours at 
-20ºC. This will provide rigidity to the sample without
polymerization11.
After the impregnation, the sample is embedded in
methyl methacrylate at a constant temperature ranging
from 5°C up to 10°C, depending on the methyl
methacrylate used. High temperatures will lead to a
quick polymerization, with the formation of CO2 bub-
bles inside the sample container16.
The methyl methacrylate solution should be poured
over the bone sample in a glass mold, leaving a small
space for air, so that the bottle does not break with the
increasing temperature, during the reaction. If there is
too much air inside the bottle it may take too long to
polymerize. After polymerization, the mold is broken
and the block with the sample inside is cut in a paral-
lelepiped shape with a plaster cutter. However, other
protocols do exists according to the sample characte -
ristics, as it is possible to adapt the protocol by chan -
ging the duration of the sample processing steps and
temperature conditions (for instance in the cases of
samples that may be too thick or too fatty). 
cuttInG
Cutting is performed in a microtome machine with a
tungsten blade, capable of cutting calcified bone samples. 
The block is placed in the microtome, orienting the
sample with the cortical bone perpendicular to the
edge of the blade. The cuts should be 5-10µm in thick-
ness, according to the technique to be performed. For
example, in the case of structural and static parameters
the thickness must be approximately 5 -7µm, on the
other hand in the case of dynamic parameters (name-
ly tetracycline incorporation) the thickness required
is 7-10µm, allowing a better intensity of tetracycline
fluorescence. 
The cut bone samples are then placed on glass slides
that have already been wiped with alcohol 96%. Once
on the glass slide, the bone sample should be stretched
out with the aid of a brush to avoid sample wrinkling16.
To keep the bone specimen stretched and attached to
the slide, a polyethylene film is placed on its surface
FIGurE 1. Bone biopsy showing the trephine of the drill with
the cylindrical sample of bone already obtained
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followed by 48 hours of pressing at 55ºC. The cutting
stage is then followed by staining.
Staining allows for the differentiation between struc-
tural components and cells within the tissue. There are
several different stains available that might be used ac-
cording to the objectives of the study.
stAInInG
The histological staining is specific to target the de-
sired structures13. Dyes used have affinity for specific
structures allowing their visualization. There are dif-
ferent staining techniques available, such as toluidine
blue, von Kossa, phosphatase acid, goldner trichrome,
solochrome azurine and perls method stain13, 17. In ad-
dition to selective staining, imunohistochemistry tech-
nique can also be used to allow antigen detection by
using antibodies, providing additional information.
The toluidine blue staining uses a basic dye, which
stains all the structures in different shades of blue.
Toluidine blue stains mineralized bone as violet blue
and the osteoid as pale blue. This staining also allows
the visualization of cement lines, which correspond to
different stages of bone growth18. 
The von Kossa technique is ideal when a highest
contrast between calcified bone and osteoid is needed.
Silver nitrate stains the calcified tissue (bone) black,
while the trichrome will turn the non-calcified tissue
(osteoid) into a red colour17,19.
The acid phosphatase (a lysosomal enzyme present
in bone cells) coloration allows the visualization of os-
teoclasts within bone tissue17,20. With this technique
osteoclasts will stain red because they have a content
rich in acid phosphatase, while the rest of the tissue
will have a blue colour due to toluidine blue which is
used as a contrast. 
The Goldner Trichrome technique allows a highest
contrast between osteoid and calcified bone, better for
cellular detail. Light green stains the calcified tissue
(bone) green, while the Orange G and Ponceau will
turn the non-calcified tissue (osteoid) into a orange/
/red colour21. 
Solochrome azurine staining is ideal to identify the
aluminium deposits commonly present in cement and
mineralization lines22. This technique stains alumini-
um deposits with a violet/purple colour.
Perl s method stain allows the visualization of reac-
tive ferric iron.  The sections are treated with hy-
drochloric acid to release ferric ions reacting with
potassium ferrocyanide to produce a blue com-
pound23,24. 
tEtrAcyclInE lAbEllInG
Tetracycline is fluorescent compound that has the abi -
li ty to bind to mineralization fronts of amorphous
mine rals, labelling them with a yellow-green colour
under fluorescent light, thus acting as a marker for
bone formation and mineralization. Tetracycline
should be taken (orally or parenterally) 21 days before
bone biopsy. Two doses of this compound are usually
taken with an interval of 10 days. This is to allow the
identification of two distinct lines (usually synthesized
within 3 days) that represent two phases of minerali -
zation7,11. This technique allows the dynamic assess-
ment of bone metabolism1. In order to perform tetra-
cycline labelling and optimize its visualization, 
bone sections should be cut ranging from 7-10µm in
thickness.  
HIstomorpHomEtrIc AnAlysIs
After processing and staining, the bone slides are vi-
sualized in a microscope equipped with a camera. Cur-
rently there are several softwares with specific tools
that allow histomorphometric analysis. These soft-
wares are optimized for quantitative microscopy and
the measurements can be performed manually or au-
tomatically, in a semi-quantitative or quantitative set-
up25-28. If the sample does not have a homogeneous tra-
becular distribution, the error increases when mea-
surements are performed automatically or semi-quan-
titatively. The evaluation is stoichiometric and
has a set of  image analysis tools for the acquisition
of results by the assignment of pixels. The sample is 
analyzed using a gray scale that corresponds to 
different tissue densities29. Within the selected areas,
regions with bone debris should not be considered due
to its interference with the quantification procedure
(Figure 2).
The manual grid is useful to divide the sample in
several fields with the same dimensions, allowing an
easier quantification and analysis of the histomorpho-
metric parameters (Figure 2). The selected area must
be similar in all samples and the same parameters mea-
sured in order to standardize the analysis30,31. The to-
tal sample area analyzed will depend on the require-
ments of the study. 
This technique performs the acquisition of images
and data in two dimensions but it can provide mea-
surable parameters for a three-dimensional evaluation
that can be obtained using stereological formulae.   
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HIstomorpHomEtrIc pArAmEtErs
Histomorphometric parameters are described accor -
ding to the American Society for Bone and Mineral Re-
search (ASBMR) nomenclature committee (Table I).
Several histomorphometric detailed parameters are
listed below:
1. Bone area (2D, volume in 3D) is the percentage of
occupied area by calcified bone in relation to the
total area.
2. Trabecular width (2D, thickness in 3D), (Tb.Wi)
= (2xB.Ar)/B.Pm, distance across individual tra-
beculae.
3. Trabecular number (Tb.N) = (B.Ar/T.Ar)/Tb.Wi, num-
ber of trabeculae that a line through a trabecu lar com-
partment would hit per millimetre of its length.
4. Trabecular separation (Tb.Sp) = (1/Tb.N) –
Tb.Wi, distance between trabeculae.
5. Osteoid with (2D, osteoid thickness in 3D) is mea-
sured at four or eight equidistant points on seams
longer than 600µm in length. A minimum of 20
seams per biopsy is measured on the same sections
used for osteoid perimeter. All seams with a width
of 3µm or more are included.
6. Osteoid perimeter (2D, osteoid surface in 3D) is
the percentage of the bone surface occupied by os-
teoid in relation to the total bone perimeter.
7. Osteoid area (2D, osteoid volume in 3D) is the per-
centage of area by osteoid in relation to the total area. 
8. Osteoblast perimeter (2D, osteoblast surface in 3D)
is the percentage of the bone perimeter occupied by
osteoblasts in relation to the total bone perimeter.
FIGurE 2. Trabecular bone sample with a special grid, which
allows the direct measurement of parameters
tAblE I. HIstomorpHomEtrIc pArAmEtErs
Parameters Abbreviations
Strutural parameter
Bone volume/Tissue volume (%) BV/TV
Trabecular thickness (μm) Tb.Th
Trabecular number (/mm) Tb.N
Trabecular separation (mm) Tb.Sp
Static formation parameter
Osteoid Thickness (μm) O.Th
Osteoid surface/bone surface (%) OS/BS
Osteoid volume/bone volume (%) OV/BV
Osteoblast surface/bone surface (%) Ob.S/BS
Dynamic formation parameter
Mineralizing surface/bone surface (%) MS/BS
Mineral apposition rate (mm/d) MAR
Mineralization lag time (d) Mlt
Bone formation rate/bone surface BFR/BS
(mm3¥mm-2xy-3)
Static resorption parameter
Osteoclast surface/bone surface (%) Oc.S/BS
Eroded surface/bone surface (%) ES/BS
BV: Bone volume; TV: Tissue volume; Tb: Trabecular; Th: Thickness;
N: Number; Sp: Separation; O: Osteoid; OS: Osteoid surface; 
BS: Bone surface; OV: Osteoid Volume; Ob.S: Osteoblast surface;
MS: Mineralizing surface; MAR: Mineralizing apposition rate; 
Mlt: Mineralizing lag time; BFR: Bone formation rate; 
Oc.S: Osteoclast surface; ES: Eroded surface
9. Mineralizing perimeter (2D, mineralizing surface
in 3D) is assessed as the extent of bone perimeter
that exhibits either single or double labels. Mea-
surements are performed using fluorescence mi-
croscopy.
10. Mineral apposition rate is calculated as the mean dis-
tance between double labels divided by the time pe-
riod between the administrations of the two labels.
11. Mineralization lag time is the interval between de-
position and mineralization of matrix.
12. Bone formation rate is the amount of bone formed
per year on a given bone surface.
13. Eroded perimeter (2D, eroded surface in 3D) is the
percentage of bone perimeter occupied by eroded
cavities.
14. Osteoclast perimeter (2D, osteoclast surface in 3D)
is the percentage of bone perimeter covered by os-
teoclasts.
Histomorphometric measurements can be deter-
mined using a specific software which analyzes the mi-
croscopic images. 
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Direct measures can be done manually, outlining
the sample (Figure 3) or semi-automatically using a
grey scale (Figure 4). Several measurements are indi-
rect, requiring the directly values previously obtained.
HIstomorpHomEtrIc ApplIcAtIons
Histomorphometry evaluates in vivo bone metabolism
and microarchitecture and can contribute to the diag-
nosis of bone-related diseases. 
Regarding diagnostic application, histomorphome-
tric analysis of bone michroarchitecture has been used
for the detection of metabolic bone diseases such as
osteomalacia32, renal osteodistrophy9,14,15,33-35 and os-
teoporosis36. Measurements of bone turnover, minera -
lization and volume, help to classify the different disea -
ses since it reveals different histomorfometric profiles33
(Table II).
Osteomalacia is a metabolic disease that involves
abnormal mineralization of the bone matrix. Histo-
morphometric findings reveal an impairment of bone
mineralization characterized by increased osteoid
thickness, surface and volume. In severe cases, dy-
namic parameters are impossible to access, as the dis-
tance between double labels of tetracycline are unde-
tectable, reflecting absence of mineralization37. 
Parfitt et al, developed a mineralization index, based
on several histomorphometric parameters. This is an
important key tool to analyze bone biopsies for the
diag nosis of different kinds of bone diseases such as re-
nal osteodystrophy and osteomalacia32.
Histomorphometry is also useful in other bone
metabolic disorders such as osteoporosis, where it is
used in randomized controlled trials to monitor the ef-
fect of new drugs in bone microarchitecture and bone
remodelling6,7.
In addition, histomorphometry measures some as-
pects of bone quality such as microarchitecture, texture
of the osteoid matrix and the presence of changes in
the mineralization process of both surface and inter-
stitial layers36. 
HIstomorpHomEtry lImItAtIons
One of the major limitations of histomorphometry is
the invasive acquisition of the sample requiring  bone
biopsy1. A bone biopsy carries potential complications
such as pain, hematoma, wound infection and, rarely,
neuropathy38. Additionally, the information provided
by the biopsy only gives a “photo”/time frame of a dy-
namic process.
Bone microarchitecture can be assessed by new non-
invasive techniques, such as micro-CT, using 3-di-
mensional reconstruction. They have a strong poten-
tial for microstructural analysis, however, only provide
structural information useful for the diagnosis of os-
teoporosis but inadequate for other metabolic bone
diseases.
Histomorphometry per se is time consuming com-
pared to the conventional histology technique. In ad-
FIGurE 3. The trabecular area is obtained outlining the
trabecula sample. This procedure is manual
FIGurE 4. Trabeculas are selected using the gray scale of the
software, allowing the area quantification. This procedure is
semi-automatic, because the investigator must decide what he
considers not to be trabecula
tAblE II. HIstomorpHomEtrIc FIndInGs In 
dIFFErEnt bonE condItIons
Bone 
Bone disease Turn-over Mineralization volume
Osteoporosis High Normal Low
Osteomalacia Low Abnormal Low
Adynamic bone Low Normal Low
Osteitis fibrosa High Normal High
Bone Paget High Abnormal Normal
disease
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dition, histomorphometry needs highly specialized
technicians to prepare samples and to deal with specific
equipment1. 
conclusIon
Bone histomorphometry is a commonly used technique
in the field of medical sciences. It has been used not
only as a diagnostic method in clinical practice (osteo-
malacia and renal ostheodistrophy) but also as an im-
portant tool in medical research. 
The main challenge for the future of histomor-
phometry is to minimize tissue disruption in order to
keep the structure close to the in vivo appearance. 
Although micro-CT, has recently been proposed 
for the analysis of bone microarchitecture and 
microstructure, bone histomorphometry is still the
gold standard for bone metabolic and mineralization
evalua tion. 
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